Related Experiment Video
Updated: May 15, 2026
05:16
Sleeve Gastrectomy in Mice using Surgical Clips
Published on: November 14, 2020
Changes in GIP gene expression following bariatric surgery.
Erin Moran-Atkin1, Fred Brody, Sidney W Fu
1Department of Surgery, The George Washington University Medical Center, 2150 Pennsylvania Avenue NW, Washington, DC 20037, USA. erinmoranatkin@gmail.com
Surgical Endoscopy
|January 12, 2013
Summary
Bariatric surgery, particularly Roux-en-Y gastric bypass (RYGB), significantly improves type 2 diabetes (T2D) by increasing glucose-dependent insulinotropic polypeptide (GIP) gene expression, supporting the foregut hypothesis.
Area of Science:
- Endocrinology and Metabolism
- Bariatric Surgery and Diabetes Management
Background:
- Bariatric surgery leads to substantial improvements in type 2 diabetes (T2D).
- Incretins, such as glucose-dependent insulinotropic polypeptide (GIP), are implicated in T2D.
- Investigating GIP in bariatric surgery patients offers insights into T2D resolution.
Purpose of the Study:
- To analyze the relationship between bariatric surgery and GIP gene expression in T2D patients.
- To explore the potential role of GIP in T2D remission following Roux-en-Y gastric bypass (RYGB) and gastric banding.
Main Methods:
- Twenty-three morbidly obese patients (12 RYGB, 11 gastric banding) with and without T2D were studied.
- Preoperative and postoperative blood samples were analyzed for GIP gene expression using real-time quantitative PCR.
- Statistical analysis was performed using Student's t test.
Main Results:
- T2D resolved or improved in 83.3% of diabetic patients post-surgery.
- RYGB patients showed a significant postoperative increase in GIP gene expression (4.36-fold, p=0.02).
- Improved T2D correlated with a 3.4-fold increase in GIP gene expression (p=0.01).
Conclusions:
- This study demonstrates a significant increase in GIP gene expression after RYGB, correlating with T2D resolution.
- Anatomical changes induced by RYGB may drive these GIP expression changes.
- GIP emerges as a potential key peptide in the foregut hypothesis for T2D remission.
Related Concept Videos
01:58Cell Specific Gene Expression
Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...